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Abstract 
3,4-methylenedioxy-N-methylamphetamine (MDMA) produces diverse pro-social effects. Cognitive training methods rooted in Eastern 
contemplative practices also produce these effects through the development of a compassionate mindset. Given this similarity, we 
propose that one potential mechanism of action of MDMA in psychotherapy is through enhancing effects on intrapersonal attitudes (i.e. 
pro-social attitudes towards the self). We provide a preliminary test of this idea. Recreational MDMA (ecstasy)-users were tested on 
two occasions, having consumed or not consumed ecstasy. Self-critical and self-compassionate responses to self-threatening 
scenarios were assessed before (T1) and after (T2) ecstasy-use (or no use), and then after compassionate imagery (T3). Moderating 
roles of dispositional self-criticism and avoidant attachment were examined. Separately, compassionate imagery and ecstasy produced 
similar sociotropic effects as well as increases and reductions in self-compassion and self-criticism respectively. Higher attachment-
related avoidance was associated with additive effects of compassionate imagery and ecstasy on self-compassion. Findings were in 
line with MDMA’s neuropharmacological profile, its phenomenological effects and proposed adjunctive use in psychotherapy. However, 
although conditions were balanced, the experiment was non-blind and MDMA dose/purity was not determined. Controlled studies with 
pharmaceutically pure MDMA are still needed to test these effects rigorously.  
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Introduction 
 Recreational users of 3,4-methylenedioxy-N-
methylamphetamine (MDMA), or ‘ecstasy,’ report a number of 
acute desirable effects. Principal among these is the experience of 
enhanced interpersonal relatedness, or a sense of connection to 
others [Bedi et al., 2009, Dumont et al., 2009]. Indeed, the 
experimental effects of MDMA are primarily reported in the social 
domain and these may relate to its unique and complex 
pharmacology as a broad-acting pro-monoamine-, vasopressin- 
and oxytocin-ergic compound [Broadbear et al., 2013, Parrott, 
2013]. The interaction between these neurotransmitter systems is 
implicated in social approach, reward and attachment in 
mammalian brain systems that evolved specifically to promote 
affiliation among conspecifics, enabling cooperation within large 
social groups [Depue et al., 2005].  It is proposed that the evolution 
of complex social-cognitive capabilities in humans was 
accompanied by the development of self-referential cognitive 
processes, including the tendency toward critical self-evaluation 
[Gilbert, 2000]. High levels of self-criticism are a risk factor for 
psychopathology following stressful life events [Lassri et al., 2013, 
Pinto‐Gouveia et al., 2013]. Increased self-criticism is also a core 
feature of various psychological disorders [Gilbert et al., 2001]. By 
contrast, effects of self-soothing arise from the  neural systems 
responsible for affiliative bonding referred to above [Depue et al., 
2005], which are compromised in psychological disorders. 
Psychotherapists have long recognised the need to develop 
treatment strategies that subvert the cognitive processes 
responsible for negative self-referential thinking and for 
upregulating self-soothing processes [Linehan, 1993].  
Recently, novel psychotherapeutic procedures, inspired 
by Eastern meditative practices which emphasise ‘loving kindness’ 
and compassion have been developed and show promise in the 
treatment of a range of disorders [Gilbert, 2014;Hofmann et al., 
2011], including psychosis [Laithwaite et al., 2009; Braehler et al., 
2013] and personality disorder [Lucre et al., 2013]. Other 
therapeutic approaches emphasise the evolutionary psychology of 
attachment and bonding and the capacity to counteract the 
influence of negative self-referential thinking through a variety of 
compassion-focused exercises [Gilbert, 2014]. For example, 
Compassion-Focused Therapy (CFT) involves the use of 
compassionate imagery (CI) to direct benevolent, nurturing, 
warmly-regarding and compassionate feelings towards the self 
[Gilbert, 2014].  
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Self-directed compassion is not only a potential antidote 
to maladaptive feelings of shame and guilt in psychopathology but 
may also have a role in promoting well-being and resilience in the 
absence of psychological disorder [Wallace et al., 2006]. Expert 
mediators show evidence of neural remodelling and alterations in 
neural [Lutz et al., 2008, Weng et al., 2013] and epigenetic 
[Kaliman et al., 2014] responses to social stress. During 
meditation, experts can achieve states of ecstasy and 
transcendence. However, as with other forms of ‘mind training,’ 
expertise is generally only achieved after intensive and prolonged 
practice. Alternatively, transcendence and profound personal 
insights can also be gained through the use of psychedelic drugs. 
While the legitimacy or authenticity of such insights might be 
questioned - particularly when effects are short-lived rather than 
transformative - it is also true that under certain conditions, 
including those of the controlled laboratory setting, some 
compounds (notably psilocybin) can produce lasting and positive 
personality changes after only a single dose [Griffiths et al., 2011]. 
Such ‘restructuring’ of the personality was previously only thought 
to be possible through prolonged and intensive psychotherapy. 
These observations, along with a reconsideration of evidence from 
non-controlled studies that predate the scheduling of these drugs, 
have resulted in a revival of interest in the use of psychedelics as 
therapeutic agents [Nutt et al., 2013].   
Similarly, the mixed-profile psychedelic/stimulant drug 
MDMA has been tested in a number of small-scale clinical trials as 
an adjunct to psychotherapy [Mithoefer et al., 2011, Mithoefer et 
al., 2013, Oehen et al., 2013].While these studies show that MDMA 
is a promising therapeutic agent, it is most commonly used as a 
recreational drug (i.e. ecstasy). A recent Australian survey 
suggested approximately one in four 20-29 year olds has tried the 
drug and 10% have used it in the past month [Australian Institute of 
Health and Welfare, 2011]. Its pro-social effects include feelings of 
love [Bedi et al., 2010], sense of connection and compassion; 
[Sumnall et al., 2006] which have been widely documented in 
controlled studies and amongst recreational users, who frequently 
report using ecstasy specifically to obtain these effects [Morgan et 
al., 2013]. These perceptual, psychedelic and transcendental 
effects [Dumont et al., 2006] particularly motivate its use amongst 
those seeking spiritual awakening and enlightenment, with some 
users combining Eastern meditative practices with ecstasy to 
achieve insights and transcendent states [Watson et al., 1991]. 
Alternatively, some recreational users take the drug to help them 
cope with adverse life events, namely as a form of self-medication 
[Moonzwe et al., 2011], although the extent and nature of 
psychological changes that accompany such use remains unclear. 
It is of interest to determine whether the unique 
sociotropic effects of MDMA extend to intrapersonal attitudes, 
particularly self-criticism and self-compassion. In line with the 
proposed use of MDMA as an adjunct to psychotherapy and the 
apparently overlapping phenomenological effects of MDMA and 
compassion-oriented practices, it is of particular interest to 
examine the combined effects of MDMA and CI on self-criticism 
and self-compassion. Here we use a within-subjects, repeated 
measures, naturalistic experimental design to test the effects of CI 
and ecstasy in recreational ecstasy users. Ecstasy-use has 
typically been associated with the dance scene, and naturalistic 
studies have tended to focus on determining whether ecstasy is 
associated with acute neurotoxic effects (i.e. cognitive impairment) 
by examining users’ performance in the presence and absence of 
the drug [Rogers et al., 2009]. In contrast, using the same research 
strategy, our aim is to determine whether subjectively positive or 
therapeutically-relevant effects related to self-attitude can also be 
attributed to ecstasy (and by implication, to MDMA) by studying its 
effects in recreational users. Our hypotheses were broad-based: 
ecstasy’s well-characterised pro-affiliative effects were expected to 
extend to improvements in self-attitudes (reduced self-criticism 
and/or enhanced self-compassion). In line with MDMA’s ability to 
enhance psychological treatment effects, we predicted that effects 
of CI - a psychological procedure used in a bona fide 
psychotherapy (Gilbert, 2010) - would be enhanced by ecstasy.  
We also examine whether any interaction between CI 
and ecstasy is moderated by attachment characteristics. This is of 
particular interest because attachment security provides the basis 
for care-related behaviours and feelings; conversely those with 
problematic forms of adult attachment, that is, avoidant or anxious 
styles of relating in close relationships, may experience barriers to 
(self-) compassion [Mikulincer et al., 2005] and, in the context of 
mood disorders, may benefit from compassion-oriented treatments 
to overcome these barriers [Gilbert, 2014]. Adult attachment 
patterns have implications for adaptive interpersonal functioning 
but can also resemble personality styles that are a predisposition 
for depression [Blatt, 1974]. Moreover, the only other study 
examining the neuropharmacology of self-compassion found that 
the effects of oxytocin were moderated by attachment-related 
avoidance [Rockliff et al., 2011]. The same study found similar 
moderating effects of trait self-criticism. Since the effects of 
ecstasy may be partially mediated by oxytocin, it is of interest to 
also investigate the moderating role of trait self-criticism in the 
current study.  
 It should be noted that ecstasy is a recreational drug and 
that much of what is sold as ecstasy contains varying amounts of 
MDMA along with other compounds. A recent analysis of ecstasy 
tablets showed that 70% contained only MDMA whereas 7% 
contained a mixture of MDMA and other stimulant compounds 
[Brunt et al, 2012]. Studies on the neurotoxicity or ‘beneficial’ 
effects of MDMA in which ecstasy rather than pharmaceutical-
grade MDMA is examined must therefore be considered in the 
context of the relative impurity of the drug being investigated. 
Methods 
Participants  
Ecstasy users were recruited from the local community through 
word of mouth and snowball sampling. Participants who became 
aware of the study and were interested in participating were invited 
to contact the team for further information. Participants were 
screened via telephone interview to exclude those with history of 
self-declared psychotic illness, current mental health problems 
requiring treatment, serious physical illness requiring treatment, 
pregnancy or breast-feeding.  
A power calculation based on an assumption of medium 
effects (f=0.25) in a repeated measures ANOVA interaction (Time x 
Session), with β=0.8, α=0.05, assuming strong correlations (r=0.7) 
between primary repeated measures variables across time, 
suggested a sample size of n=18. Twenty participants began and 
completed the study (7 women; 13 men). Of the women 
participants, five used hormone-based contraception, two did not. 
Participants generally did not practice meditation (n=16), although 
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some meditated with differing frequencies (<1/week: n=2; >1/week: 
n=2).  
All gave written, informed consent at the start of the first 
session during which they were made aware that they could 
withdraw from the study at any time without needing to give a 
reason. The study was approved by the UCL Graduate School 
Research Ethics Committee.  
Design and Procedure 
A naturalistic within-subjects design was used, with all 
participants completing one session in which they took ecstasy 
recreationally prior to a compassionate imagery (CI) task , and a 
second session (control) in which they took no drug prior to CI. 
Testing sessions took place between 6-14 days apart. Participants 
informed the experimenter of their plans to use ecstasy (usually 
when they were not intending to go to a party or clubbing) and the 
experimenter arranged the control session to occur either before or 
after the CI + ecstasy session, at the convenience of the 
participant while ensuring session balance across participants. The 
order of the CI + ecstasy session, and the control session was 
balanced such that 10 participants completed the CI + ecstasy 
session first. 
Participants were asked to refrain from any drugs (except 
caffeine and nicotine) for 24 hours prior to each session and 
provided a urine drug-screen at the start of each of the two 
sessions. Testing sessions were conducted individually in a quiet 
room in participants’ homes. On both testing sessions state 
measures of affect (the PANAS and TPAS; see below) were 
administered along with a scenario-based measure (the SCCS, 
see below) which required participants to imagine life-events 
intended to induce negative self-referential thinking and then 
immediately rate themselves on a number of self-compassion- and 
self-criticism-related dimensions at three time points: T1 (baseline), 
T2 (40 + 13 mins) after T1), and T3 (~20 min after T2; see Figure 
1). Immediately after T1, participants took their ecstasy via their 
normal route of administration. Assessment at T2 (i.e. 
administration of PANAS, TPAS and SCCS) occurred after 
participants indicated that they were experiencing ‘peak effects’ of 
ecstasy (relative to previous experiences with the drug). 
Immediately after T2 assessment, participants underwent the CI 
task, after which they completed the same measures again (T3). 
As such, assessment of affect, self-compassion and self-criticism 
at T2 occurred only in the presence of ecstasy (CI + ecstasy 
session) or its absence (control session), whereas assessment of 
these constructs at T3 represented the combined assessment of 
ecstasy and CI effects (CI + ecstasy session) or CI effects alone 
(control session).   
Seven participants insulfated ecstasy and 13 took it 
orally; differences in timing of self-judged ‘peak effects’ account for 
the variability in T2 with respect to T1 (the T1 and T2 interval did 
not differ between insulfating and orally ingesting participants).  
During the control session, participants completed a 
closely matched procedure, with two main exceptions: they did not 
consume any substance, and they completed additional trait 
questionnaires (between T1 and T2).  
State Measures 
The choice of measures in this experiment was informed 
by a previous study examining the effects of oxytocin on CI 
[Rockliff et al., 2011] and consisted of pre-/post- state measures to 
assess effects of CI + ecstasy on affective state and self-attitudes. 
In addition ecstasy-specific subjective measures were used to 
assess subjective changes in state following drug ingestion. 
 Ecstasy-related Mood and Symptoms Scale: A set of 
visual analogue scales specifically assessed ecstasy-related mood 
and symptoms, including compassion and empathy. Items included 
euphoria, energetic, jaw clenching, trust, wanting to be with others, 
closeness to others, compassion for others, compassion for self, 
empathy, sensitivity to colour, self-confidence. Anchors (e.g. not at 
all [euphoric] and very [euphoric]) were used at the extremes of the 
scales (0 and 10). 
 Drug experience/ expectancy: On the CI + ecstasy 
session, participants rated the (expected) strength of effect of their 
ecstasy (‘How strongly will it affect you/is the effect?’), and its 
purity (‘How pure is the MDMA?’) on a 7 point drug 
expectation/experience scale (1=not at all, 7=extremely) before 
and after taking the drug. 
 Experience of Compassionate Imagery Questions: 
Participants responded to items about their experience of CI on 
Likert scales (1=low-10=high), particularly of receiving compassion: 
resistance, momentary tension, ‘effort creating,’ clarity, ‘feeling 
moved’ and sadness in response to CI. An additional question 
assessed the ‘ease’ with which participants experienced their 
image, which was intended to embody wisdom, kindness, warmth 
and care. These items and their scoring are described by Rockliff 
and colleagues [Rockliff et al., 2011]. 
 Positive and negative affect: The 10-item version of the 
Positive and Negative Affect Schedule (PANAS) was used 
[Thompson, 2007]. Each of the five positive and five negative items 
(single-word adjectives) were rated on Likert scales (1=not at all-
5=very much so). Participants were instructed to rate their current 
feelings. Additionally the Types of Positive Affect Scale (TPAS) 
[Gilbert et al., 2008] assesses the extent to which people 
experience different types of positive affect. The TPAS consists of 
18 words, which individuals rate on a 5 point scale to indicate the 
extent to which each word characterises them. There are three 
subscales for different forms of positive affect: activating, relaxed 
and safeness/contentment. Participants were instructed to respond 
to items in relation to how they felt right now. 
 State self-compassion and self-criticism: The Self-
Compassion and Criticism Scale (SCCS; [Falconer et al., 2015] is 
a situational measure of self-compassion and self-criticism. It 
consists of five scenarios which are potentially self-threatening and 
which participants are instructed to vividly imagine, as if they were 
occurring at the current moment. After imagining each scenario, 
participants immediately rate their reaction towards themselves. 
While the scenarios would normally produce negative self-
referential thinking, participants can also respond with varying 
degrees of self-soothing, reassurance, and compassion (self-
compassion items) as well as harshness, contempt and self-
criticism (self-criticism items) on 7-point Likert scales (1 = not at all 
to 7 = highly). Psychometrically, the SCCS is separated into two 
orthogonal scales (self-criticism and self-compassion). The scales 
have excellent or good reliability with Cronbach's alphas of 0.91 
and 0.87 respectively [Falconer et al., 2015], and recent research 
suggests that the SCCS scale is a useful tool in repeated 
measures designs that examine the effects of experimental 
compassion-focused interventions [Falconer et al., 2014].  
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Mood, trait and drug-use measures 
 Depression: The Beck Depression Inventory II (BDI-II) 
[Beck et al., 2005] consists of 21 sets of 4 statements (scored from 
0 – 3) relating to symptoms of depression. Participants select the 
statement that best describes how they have felt over the previous 
two weeks. Higher total scores indicate more severe symptoms of 
depression. 
 Adult Attachment: The ‘close relationships’ version of the 
Revised Adult Attachment Scale was used [Collins, 1996]. This 
consists of 18 statements, with three subscales (‘close,’ ‘depend’ 
and ‘anxiety’). Each statement is rated on a 5 point Likert scale, 
indicating the extent to which it is characteristic of how the 
participant generally feels in important close relationships in their 
life (1=not at all characteristic of me-5 = very characteristic of me). 
The close subscale measures how comfortable an individual is with 
closeness, tapping attachment-related avoidance. The normative 
value for this subscale is 3.20, based on a large-scale cluster 
analysis of different attachment styles [Collins, 1996]. This 
subscale was of particular interest in this study given the 
moderating role of attachment-related avoidance in oxytocin’s 
effects on self-compassion [Rockliff et al., 2011]. Participants were 
classified as relatively low on attachment avoidance (mean score + 
SD: 3.30 + 0.70) or high on attachment avoidance (mean score + 
SD: 4.57 + 0.37) based on a median split of their scores, which 
were significantly different (t(18)=5.073, p<0.001).  
 Trait self-criticism: Dispositional self-criticism – the 
persistent tendency toward negative self-evaluation was assessed 
using the ‘inadequate self’ subscale of the Forms of Self-
Criticizing/attacking and Self-Reassuring Scale [Gilbert et al., 
2004]. Responses are given on a 5 point Likert scale (0= not at all 
like me, 4=extremely like me). Participants were classified as ‘high’ 
and ‘low’ scorers on self-criticism based on a median split of 
scores as per Rockliff et al [Rockliff et al., 2011] who showed that 
self-criticism as measured by the inadequate-self subscale 
moderated the response of oxytocin on experiences of self-
compassion.   
 Drug-use: Participants were asked about their drug-use 
using a semi-structured interview designed for young UK drug 
users [Freeman et al., 2012]. Alcohol, tobacco, ecstasy, cannabis, 
cocaine, ketamine, hallucinogens, mephedrone and amphetamine 
were rated for their most recent consumption (days ago), length of 
use (years), days per month use and ‘amount per session’ (various 
units) were recorded for each drug type. Participants were 
considered ‘regular users’ of a particular drug if they used the drug 
at least twice a month. Objective assessment of drug use was 
conducted using a drug screen urine test cup (Alere, Abingdon, 
Oxfordshire, UK) which assesses for the presence of a range of 
illicit and prescription pharmaceuticals on each session.  
Compassionate imagery 
Participants completed a guided CI exercise, by listening 
to three MP3 recordings through headphones. The recordings 
corresponded to: (i) description of an ideal compassionate being, 
(ii) relaxation through rhythmic breathing and (iii) active 
engagement with the ideal compassionate being in imagery. The 
exercise was based on the type used in CFT and is described at 
length in CFT manuals (e.g. Gilbert, 2010). A brief outline is 
provided here (the script is available from the corresponding 
author). Participants listened to a recording outlining the nature of 
compassionate mental imagery which provided details about the 
nature of an ideal ‘compassionate being,’ and were told its qualities 
included unconditional positive regard, deep commitment, wisdom, 
acceptance and strength of mind. The description was deliberately 
permissive, such that participants could generate any type of 
compassionate figure, according to their preference. After a pause 
to allow for questions, participants were guided through five 
minutes of ‘rhythmic breathing’ and awareness. After this, 
participants were asked to develop an image of an ideal 
compassionate being and then receiving compassion from this 
being, focusing sequentially on various qualities of (or feelings 
arising from) deep commitment, strength and dependability, 
wisdom and understanding, acceptance, warmth, loving kindness, 
care and concern, and compassion flowing from the 
compassionate being. The total duration of the entire (three 
recordings) CI procedure was 18 min and was the same on both 
sessions.  
Prior to, and immediately after CI, participants completed 
state questionnaires (PANAS, TPAS, SCCS) as well as the 
experience of compassionate imagery questions. Note, participants 
were not given any specific instructions to bring compassionate 
images or feelings to mind while completing these 
question(naire)s.  
Statistical analyses. 
Data were analysed using 2 x 3 repeated measures 
ANOVA, with Session (CI + ecstasy) and Time (T1, T2 and T3) as 
within subject factors and positive/negative mood states and state 
self-compassion and self-criticism as dependent variables. 
Repeated measures ANOVAs (2 x 3 x 2) were also used to assess 
effects of ecstasy-use on self-compassion and -criticism 
respectively, with dispositional self-criticism and attachment-related 
avoidance status (high and low) as a between subjects factor. 
Paired samples t-tests were used in planned comparisons to 
analyse ‘experience of compassionate imagery’ items and for 
follow-up analyses of significant interactions. Exploratory 
correlations were conducted using Spearman’s Rho () 
Where assumptions of sphericity were violated, Greenhouse 
Geisser corrections were applied and adjusted degrees of freedom 
reported.  
Figure 1: Timeline of the experimental procedure permitting a comparison of the 
effects of compassionate imagery and ecstasy, both alone and in combination. 
State measures were assessed at T1, T2, and T3, at which point participants 
completed the Ecstasy-Related Mood and Symptoms Scale, the Positive and 
Negative Affect Schedule and the Self-Compassion and Criticism Scale. The 
Experience of Compassionate Imagery Questions were completed only at T3. 
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Results 
Demographics, trait questionnaire scores and drug use  
Participants’ mean age was 25.50 + 3.59 years. They 
had 16.5 + 1.64 years of education and negligible levels of 
depression (BDI score= 6.66+ 4.80).All reported regular use of 
alcohol, and most were regular users of both tobacco and ecstasy.  
Cannabis, cocaine and ketamine use was less frequent (Table 1).  
Urinalysis was generally consistent with self-report drug use. On 
the control session urinalyses results were either negative (i.e. 
drug-free; n=6), THC-positive (n=7) or benzodiazepine positive 
(n=2); three samples could not be interpreted. On the CI + ecstasy 
session participants were either negative (n=12) or THC positive 
(n=7); one participant was positive for opioids. 
 
 
Table 1: Participants' historic and current drug use. 
Drug experience and expectancy ratings 
On the CI + ecstasy session, participants’ ratings of their 
ecstasy experience on the expectancy/experience questions did 
not vary from the pre-(expected) to post-(experienced) interval for 
rated strength (pre: 4.70 ± 0.98, post: 4.38 ± 1.09, p>0.2), or rated 
purity (pre: 4.80 ± 0.95, post: 4.85 ± 1.18, p>0.5).  
Ecstasy-related mood and symptoms 
Main effects of Time were found for all 11 ecstasy-related 
mood and symptom factors (energy, euphoria, jaw clenching, 
sensitivity to colours, trust, wanting to be with others, compassion 
for others, closeness to others, empathy, self-confidence and self-
compassion; F values ≥ 3.63, p values ≤ 0.036, ηp2>0.16). There 
were also main effects of session for euphoria, jaw clenching, and 
sensitivity to colours reflecting higher values on the CI + ecstasy 
session (F values ≥ 4.39, p values ≤ 0.05).  
A Time (T1, T2, T3) x Session (CI + ecstasy, control) 
interaction for euphoria [F(2, 38)=27.80, P<0.001, ηp2=0.59] 
reflected an increase in euphoria at T2 compared to T1on the CI + 
ecstasy session. A similar pattern of interactions was observed for 
jaw-clenching [F(2, 38)=20.37, p<0.001, ηp2=0.52] and sensitivity 
to colours [F(1.50, 38)=13.72, p<0.001, ηp2=0.38].  
An interaction between Time and Session for ‘wanting to 
be with others’ [F(2,38)=4.60, p=0.027, ηp2=0.17] appeared to 
reflect parallel, independent effects of ecstasy and CI. Specifically, 
scores on this attribute increased between T1 and T2 on the CI + 
ecstasy session reflecting the expected sociotropic effect of 
ecstasy (t(19)=3.65, p=0.002). In addition, a similar increase was 
observed between T2 and T3 on the control session, reflecting the 
effect of CI alone (t(19)=3.214, p=0.005).  
All other interactions were non-significant (F values <3.1, 
p values >0.05). 
None of the 11 ecstasy-related mood and symptom 
factors increased significantly between T2 and T3 (all p values 
≥0.05) on the CI + ecstasy session.  
Effects of ecstasy and compassionate imagery on positive affect  
There were no main effects of Time or Session on the 
‘active’ positive affect subscale of the TPAS (F values <3.14, 
p>0.05). However there was a significant interaction between Time 
and Session [F(2,38)=3.98, p=0.027, ηp2=0.17], primarily reflecting 
a trend reduction in active positive affect between T1 and T2 
[t(19)=2.035, p=0.056] on the control session and a trend increase 
between T1 and T2 on the CI + ecstasy session [t(19)=2.017, 
p=0.058] (Table 2).  
No main effects or interactions were found for the 
relaxed or warm subscales (F values <1.5, p values > 0.25) of the 
TPAS or the positive affect subscale of the PANAS (F values < 2.0, 
p values >0.2).  
 
Table 2: Positive and negative affect over time in the control and CI-
ecstasy sessions. 
 
Effects of ecstasy and compassionate imagery on negative affect 
There was a main effect of Time [F(2,38)=9.361, 
p<0.001, ηp2=0.33] reflecting a gradual reduction in scores on the 
negative affect subscale of the PANAS on both testing sessions 
(Table 2) but no main effect of Session and no Session x Time 
interaction (F values <1.00, p values >0.4).  
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Effects of ecstasy and compassionate imagery on state self-
criticism and self-compassion  
 There was a main effect of Time [F(1.424, 
27.059)=19.039, p<0.001, ηp2=0.50] and Session [F(1,19)=5.135, 
p=0.035, ηp2=0.21] and a Time x Session interaction 
[F(2,38)=5.377, p=0.009,ηp2=0.22] on the self-criticism scale of 
the SCCS. As can be seen in Figure 2 this interaction reflects 
reduced self-criticism in response to ecstasy between T1 and T2 
(i.e. an effect of ecstasy alone; p=0.001) on the CI + ecstasy 
session and a similar reduction in response to CI between T2 and 
T3 on the control session (i.e. an effect of CI alone, p=0.015). On 
the CI + ecstasy session there was an additional decrease in self-
criticism between T2 and T3 (i.e. after CI; p=0.027; Figure 2, top 
panel, reflecting a combined effect of CI + ecstasy). Self-criticism 
scores were not associated with the effects of ecstasy on the 
‘active’ subscale of the TPAS at either of these time-points ( 
values < 0.2, p>0.4), suggesting that these effects on positive 
affect and self-criticism were independent.  
There was a main effect of Time [F(1.39, 26.34)=14.19, 
p<0.001, ηp2=0.43] and Session [F(1,19)=17.106, p=0.001, 
ηp2=0.47] but no Time x Session interaction [F(2,38)=2.15, 
p=0.131] on self-compassion scores (Figure 2, bottom panel). An 
exploratory 2 X 2 ANOVA using only T1 and T2 did show an 
interaction between Time and Session [F(1,19)=4.52, p=0.047, 
ηp2=0.19], suggesting an effect of ecstasy alone on self-
compassion but no additional effect of CI on the CI + ecstasy 
session.  
Experience of Compassionate Imagery 
Except for the ‘feeling moved [by receiving compassion]’ 
item, which was higher in the CI + ecstasy session [t(19)=2.17, 
p=0.043], other items of the Experience of Compassionate Imagery 
yielded no other difference between sessions (t values < 2.06, p 
values >0.05). 
Figure 2: Top Panel: Mean SCCS self-criticism scores + SEM at three time points 
corresponding to pre- (T1) and post-ecstasy (T2) and post-CI (T3) on the CI- 
ecstasy session and at similar intervals on the control session when CI occurred 
between T2 and T3 and no ecstasy was consumed. Bottom Panel: Mean SCCS 
self-compassion scores + SEM. In both panels, the ecstasy. A session data is 
represented by the solid black line and the control data by the dashed line. 
Moderating role of attachment-related avoidance 
There was no moderating role of attachment-related 
avoidance with respect to state self-criticism (F values <2, p values 
>0.1). However, as shown in Figure 3, there was a 3-way Session 
x Time x Group interaction for state self-compassion [F(2,36)=3.91, 
p=0.029, ηp2=0.18]. In the CI + ecstasy session, state self-
compassion increased significantly both between T1 and T2 
(reflecting an effect of ecstasy; p=0.037) and between T2 and T3 
(reflecting an additional effect of CI; p=0.021) in the high 
attachment-related avoidance group but not in the low attachment 
group (p values>0.1). In the control session, there was an increase 
in self-compassion between T2 and T3 (i.e. after CI) in both the 
high attachment-related avoidance (p=0.02) and low attachment-
related avoidance group (p=0.047).  
 
Figure 3: Moderating effect of avoidant attachment on self-compassion at three 
time-points (T1, T2, T3) on the CI-ecstasy and control sessions, as per Figure 2.  
 
Moderating role of trait self-criticism 
The other moderator of interest was dispositional self-criticism. 
There was a Group (low/high self-criticism) x Session interaction 
[F(1,18)=10.28, p=0.005, ηp2=0.36] but no other interactions 
involving Group (F values<1, p values >0.4). For self-compassion, 
there were no significant interactions involving group (F 
values<3.76, p>0.05). 
 
Discussion 
 In this study we examined the effects of recreational 
ecstasy-use and compassionate imagery (CI) on self-criticism and 
self-compassion. As such we extended the investigation of ecstasy 
effects beyond the widely-documented interpersonal domain to 
affiliative self-attitudes. While anecdotal reports suggest potent 
effects of ecstasy on self-forgiveness and self-compassion 
[Leneghan, 2013, Power, 2013] systematic studies of these effects 
have been lacking. 
The current findings were in line with our broad 
predictions: while there was a (10-point) decrease in self-criticism 
during the control session, there was a two-fold (21-point) larger 
decrease when CI occurred after ecstasy-use. There was a similar, 
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though less pronounced additional effect of ecstasy on self-
compassion. Moreover, the effects of ecstasy on CI were 
moderated by adult attachment characteristics such that those with 
greater attachment-related avoidance appeared to show enhanced 
self-compassion following ecstasy, and CI thereafter. Interestingly, 
while ecstasy had the expected sociotropic effect, with increased 
levels of ‘wanting to be with others’ after ecstasy, CI also produced 
this effect in the absence of ecstasy (in the control session), 
despite compassion being directed towards the self rather than 
others. 
The effects of ecstasy (+ CI) on self-criticism and -
compassion did not appear to reflect generalised improvements in 
mood. For instance, of the positive affect measures used here, 
only the ‘active’ subscale of the TPAS showed a Session by Time 
interaction, in line with ecstasy’s dopamine-dependent stimulant 
properties [Green et al., 2003]. Neither were these two effects (on 
positive affect and self-criticism) correlated suggesting that effects 
of ecstasy and CI on state self-criticisms and self-compassion are 
unlikely to simply reflect demand characteristics or expectancy 
effects alone. The moderating influence of attachment-related 
avoidance in particular is difficult to explain largely on the basis of 
expectancy. As such, while not biochemically verified, the effects of 
ecstasy-use are consistent with pharmacologically-induced 
modulation of self-processing. 
Aberrant processing of ‘the self’ characterises a number 
of psychiatric disorders [Northoff, 2007]. In particular, negative self-
referential processing -‘self-criticism’-underlies the aetiology and 
maintenance of this variety of psychopathologies (e.g. eating 
disorders, depression, social anxiety, body dysmorphic disorder, 
schizophrenia, personality disorders) and can be regarded as an 
important transdiagnostic factor [Gilbert et al., 2005, Schanche, 
2013]. Finding effective ways of dealing with self-criticism therefore 
remains a priority for psychiatry and clinical psychology. Various 
lines of research support the use of self-compassion-enhancing 
strategies to overcome the effects of self-criticism. Yet for some 
individuals the initial experience of self-compassion, even in 
therapeutic settings, can be challenging. In particular, those with 
high levels of self-hatred tend to exhibit a fear of compassion 
[Gilbert et al., 2011], and those with high levels of trait self-criticism 
and attachment-related anxiety tend to respond to CI with 
physiological activity resembling threat responses [Rockliff et al., 
2008]. For these individuals, compassion is a frightening and alien 
experience. As such, improved methods for overcoming barriers to 
self-soothing (e.g. by reducing self-critical responding) continue to 
be needed. 
The unique subjective and interpersonal-affiliative effects 
of ecstasy seem to be accompanied by a facilitation of positive 
intrapersonal relating, potentially allowing individuals who typically 
attempt to ward off compassionate feelings, to apprehend the 
hated, feared or wounded parts of the personality with gentleness 
and understanding. This type of approach- motivation towards 
enfeebled aspects of the self simply mirrors intentional empathic 
behaviour between individuals directed at relieving another’s 
suffering [Bartal et al., 2011].Such positive affiliative behaviour 
recruits a well-characterised set of neural systems and processes 
[Depue et al., 2005] involved in affiliative and consummatory 
reward and positive social memory, primarily mediated by 
vasopressin, oxytocin, dopamine, and their interaction. Importantly, 
these neurotransmitter systems are also strong positive regulatory 
targets of MDMA [Broadbear et al., 2013]. 
Those with higher levels of attachment-related avoidance 
(i.e. discomfort in close or intimate relationships) showed the 
clearest evidence of additive effects of ecstasy and CI, specifically 
on state self-compassion. Avoidance of affectionate bonds in 
adulthood may result in loneliness and social isolation, which in 
turn are associated with psychological and physical disorders 
[Bartholomew, 1990]. These findings therefore suggest that those 
with this particular ‘developmental vulnerability’ may experience 
the greatest positive effects from the therapeutic or recreational 
[Watson et al., 1991] combination of ecstasy and cognitive 
behavioural self-compassion enhancing practices. Attachment 
avoidance was of specific interest here because it moderated the 
effects of oxytocin on experiential aspects of self-focused CI 
[Rockliff et al., 2011]. In particular, those who were less avoidant 
(i.e. more comfortable in close relationships) appeared to 
experience greater positive effects of CI following intranasal 
oxytocin. Those findings are in the opposite direction to those 
found here (we have found greater positive effects of CI in the 
presence of ecstasy in those with high attachment avoidance), 
although they are in keeping with the occasionally contradictory 
and paradoxical findings with intranasal oxytocin in humans, which 
are strongly influenced by contextual factors [Churchland et al., 
2012]. Alternatively, the current findings are in line with the broad 
psychopharmacological effects of MDMA which may rely on 
dopaminergic influences on affiliative processing, potentially via 
interaction with oxytocin and vasopressin [Depue et al., 2005]. 
They are also consistent with the apparent ‘antidepressant’ effects 
of ecstasy seen in individuals with a vulnerability to depression 
[Majumder et al., 2012], possibly as a form of self-medication 
[Sessa, 2014]. 
While MDMA enhances psychotherapeutic outcome in 
treatment-resistant PTSD in small-scale trials, its mechanism-of-
action is unknown. In particular it is unclear which psychological 
process(es) interact with MDMA and whether additional 
psychological procedures, such as CI,  may optimise MDMA-
assisted psychotherapy. Our findings suggest this may be a 
possibility, especially since CI could easily be incorporated into the 
existing MDMA-psychotherapeutic model [Mithoefer et al., 2011] 
and is experientially consistent with MDMA-induced states. This is 
a critical consideration for combination psychological-
pharmacological treatments, since additive or synergistic 
interactions are only likely to be achieved when this kind of 
consistency is present. 
We are aware of the need to be cautious in generalising 
these findings to either non-drug using healthy populations, or 
those seeking treatment for psychological disorders. Clearly, the 
best evidence for efficacy of psychiatric treatments comes from 
well-controlled, randomised, double-blind trials. In the UK, trials of 
schedule I drugs, such as MDMA, continue to occur in a highly 
restrictive and regulated context, are expensive, and would only be 
approved on the basis of a compelling rationale for testing [Nutt et 
al., 2013]. In order to determine whether such a compelling 
rationale might exist, we decided to first test our hypotheses in a 
group of recreational ecstasy users. There are however, significant 
limitations to this approach. In this study we relied on convenience 
sampling so our participants may be non-representative in terms of 
response to MDMA. Since neither participants nor experimenters 
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were blind to treatment our study also has the same limitations as 
an open-label trial with respect to expectancy. In addition however, 
contextual factors associated with naturalistic drug-use (e.g. 
participants were tested in their own homes) may have increased 
expectancy of certain psychological effects (e.g. empathy and 
compassion). Several participants tested positive for recreational / 
medicinal compounds (THC, benzodiazepines and opioids). Of 
course, cannabinoids and benzodiazepines with long half-lives 
may have been detectable in urine but consumed some time prior 
to testing. However, except for self-declaration (no consumption 
within the previous 24 hours), we were unable to ensure that 
testing was unaffected by the presence of these compounds. 
Participants did not show all of the effects expected of MDMA (e.g. 
on compassion for others, closeness to others, trust). The absence 
of these effects may reflect insufficient statistical power or 
insufficiency of true MDMA-mediated effects arising from ecstasy 
that contained other ingredients [Brunt et al., 2012].  
An additional ecstasy-alone condition would have helped 
to increase confidence that effects at time point 3 (T3) were really 
due to the combined effects of ecstasy and CI rather than ecstasy 
alone. In particular, it is possible that the effects of ecstasy intensify 
over T2 and T3 and this alone could have resulted in the effects on 
self-compassion and self-criticism on the session when ecstasy 
was taken prior to CI.  However, none of the ecstasy-related mood 
and symptom factors increased significantly between T2 and T3 on 
the CI + ecstasy session. This might suggest that these effects had 
reached a steady state at T2.  
Finally, since ecstasy likely contains varying levels of 
other psychoactive compounds, the effects observed here cannot 
unequivocally be attributed to MDMA alone. As such we cannot yet 
claim our findings are a strong basis for supporting the combined 
therapeutic use of MDMA and compassion-focused 
psychotherapeutic procedures. Future naturalistic studies should 
seek to verify the chemical composition of the formulations used by 
recreational-users. However, the most robust rest of these 
hypotheses would be through double-blind, placebo controlled 
procedures with pharmaceutical-grade MDMA, ideally including a 
suitable active control (e.g. methylamphetamine; Bedi et al., 2010).  
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